Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers
Home › IN › MISHAWAKA › TOXUSA LABS LLC

TOXUSA LABS LLC

NPI: 1073985727 · MISHAWAKA, IN 46545 · Clinical Medical Laboratory · NPI assigned 10/21/2015

$9.62M
Total Medicaid Paid
481,356
Total Claims
371,552
Beneficiaries
149
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialKHADR, EYAD (OWNER)
NPI Enumeration Date10/21/2015

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 992 $13K
2019 56,560 $382K
2020 94,554 $2.15M
2021 86,605 $1.23M
2022 90,619 $1.92M
2023 108,632 $2.53M
2024 43,394 $1.40M

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 38,700 24,301 $2.26M
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 31,605 22,017 $1.82M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 34,111 23,730 $794K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 9,781 7,698 $654K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 7,343 5,961 $587K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 13,106 9,965 $467K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 15,322 14,029 $265K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 17,577 11,538 $225K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 1,118 1,023 $184K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 3,810 3,333 $103K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV 1,437 1,335 $93K
80354 9,858 6,993 $83K
80346 9,861 6,996 $83K
80358 9,848 6,991 $78K
80348 9,867 6,996 $78K
80364 9,841 6,978 $73K
87653 5,575 5,009 $72K
80365 9,842 6,983 $70K
87641 5,058 4,550 $65K
80324 9,872 6,994 $64K
87500 4,823 4,360 $59K
80353 9,839 6,991 $58K
80356 3,905 2,421 $53K
80338 7,864 6,134 $51K
87640 6,123 5,447 $50K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe 3,238 3,022 $50K
87486 3,294 3,004 $49K
87581 3,281 2,993 $49K
87541 2,908 2,702 $48K
80355 8,198 6,334 $47K
80360 8,258 6,350 $45K
87481 3,940 3,276 $43K
80357 7,796 6,075 $42K
80359 5,479 3,157 $41K
80366 8,156 6,317 $35K
80373 8,160 6,317 $33K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 2,947 2,549 $32K
83992 8,286 6,368 $32K
80323 4,572 4,079 $30K
87631 522 475 $30K
80345 5,263 4,425 $29K
87150 339 316 $28K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 2,541 2,274 $26K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B 281 158 $25K
80335 3,580 2,267 $25K
80368 7,975 6,215 $24K
80361 4,326 3,917 $24K
80332 4,327 3,917 $24K
80337 4,326 3,915 $24K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 662 553 $19K
80370 3,670 2,323 $18K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 2,121 1,942 $18K
87563 1,655 1,497 $18K
80350 2,854 1,583 $17K
80050 General health panel 1,488 1,399 $17K
80321 4,341 3,927 $16K
80376 4,319 3,909 $16K
87529 1,150 1,037 $14K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 1,772 1,644 $14K
80329 4,326 3,917 $14K
80349 3,050 1,751 $14K
80061 Lipid panel 2,594 2,401 $13K
87483 489 414 $11K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 277 260 $9K
83970 900 815 $9K
80372 4,316 3,906 $7K
82607 1,688 1,551 $7K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc 180 172 $6K
80369 4,315 3,905 $6K
84402 904 820 $6K
82627 931 845 $6K
84403 969 881 $6K
87181 1,046 787 $6K
83036 Hemoglobin; glycosylated (A1C) 2,082 1,927 $5K
82670 945 861 $5K
84144 936 848 $5K
87511 721 683 $5K
84270 924 838 $5K
83001 931 846 $5K
80367 4,317 3,907 $5K
83002 938 849 $5K
80305 555 382 $4K
82533 938 851 $4K
82746 1,222 1,112 $4K
82728 1,196 1,102 $4K
84481 804 748 $4K
84439 1,187 1,116 $4K
86376 1,104 1,010 $4K
87186 334 299 $3K
80053 Comprehensive metabolic panel 1,131 1,046 $3K
87505 277 244 $3K
84146 548 501 $3K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 318 298 $2K
85025 Blood count; complete (CBC), automated, and automated differential WBC count 1,286 1,180 $2K
83735 1,215 1,114 $2K
86277 522 480 $2K
86352 28 26 $2K
83540 1,223 1,114 $2K
87652 522 468 $2K
84443 Thyroid stimulating hormone (TSH) 701 651 $2K
87497 182 164 $2K
87184 330 295 $2K
87496 286 269 $2K
87081 693 532 $1K
86780 626 478 $1K
84153 196 185 $1K
83003 328 289 $1K
87498 394 353 $1K
87110 333 298 $941.90
86328 23 23 $904.60
87070 330 296 $800.56
86696 68 60 $694.61
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 50 46 $569.39
87427 333 298 $480.78
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A 28 26 $458.80
86695 81 72 $451.81
86403 512 454 $448.53
87140 333 298 $414.53
87850 28 26 $340.77
87086 Culture, bacterial; quantitative colony count, urine 68 67 $310.91
87510 28 26 $300.78
86038 43 38 $286.06
83525 57 55 $279.01
84480 45 45 $243.90
80069 41 40 $149.52
87046 30 26 $145.60
86592 73 69 $125.53
84436 26 26 $104.91
82172 25 25 $97.60
86431 33 31 $91.97
81001 212 210 $91.41
84466 27 26 $72.76
82977 39 38 $72.62
82248 59 57 $67.14
86800 18 13 $66.50
86141 25 25 $50.96
82043 26 25 $41.26
84550 41 40 $34.37
82150 24 24 $29.96
82570 25 24 $29.49
80048 Basic metabolic panel (calcium, ionized) 25 24 $27.91
84100 29 28 $26.92
80076 26 25 $24.00
85652 14 13 $23.26
86580 50 47 $17.00
82950 13 13 $12.56
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets 28 28 $0.00
86480 23 19 $0.00
87503 28 28 $0.00